Created at	Source	Raw Value	Validated value
Aug. 10, 2022, 5:30 p.m.	usa	The nasal tolerability to investigational medicinal products (IMPs);The proportion of participants who experience adverse events;The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation	The nasal tolerability to investigational medicinal products (IMPs);The proportion of participants who experience adverse events;The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation
Dec. 9, 2021, 12:30 a.m.	usa	Changes to the reverse transcription polymerase chain reaction (RT-PCR);Proportion of participants who progress to SPO2≤93;The proportion of participants who experience adverse events;The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation	Changes to the reverse transcription polymerase chain reaction (RT-PCR);Proportion of participants who progress to SPO2≤93;The proportion of participants who experience adverse events;The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuation
Oct. 7, 2021, noon	usa	Safety and tolerability of repeated doses of AD17002 in patients of mild COVID-19	Safety and tolerability of repeated doses of AD17002 in patients of mild COVID-19